open access

Vol 9, No 1 (2007)
Published online: 2007-02-01
Get Citation

Clinical application of recombinant coagulation factor VIIa in the treatment of massive bleeding in surgical patients

Grzegorz Oszkinis, Magdalena Snoch, Fryderyk Pukacki, Marcin Gabriel, Maciej Zieliński, Marek Nowak, Katarzyna Motowidło, Paweł Sobczyński, Małgorzata Nowicka
Chirurgia Polska 2007;9(1):34-42.

open access

Vol 9, No 1 (2007)
Published online: 2007-02-01

Abstract


Background: Severe perioperative bleedings related to major surgeries pose a serious medical problem due to surgical treatment. NovoSeven (recombinant activated factor VII - rFVIIa, Novo Nordisk, Denmark) accelerates local haemostasis by an exogenous coagulation system, directly stimulating factor X.
Material i methods: Three cases of the successful use of rFVIIa in the Department of General and Vascular Surgery of Poznan University of Medical Sciences have been described. The first case refers to the controlling of bleeding from a surgical wound in a female patient with idiopathic thrombocytopenia. The two others refer to the application of rFVIIa in female patients, who previously did not present any signs of haemostatic disorders.
Results: In all the cases presented, shortly after the drug’s administration, bleeding symptoms abated as confirmed by normalisation of laboratory results and haemodynamic parameters, which standard treatments had failed to produce before.
Conclusions: It is important to note that all the patients were administered a lower dose of rFVIIa than recommended by the manufacturer and described by other authors, which may indicate that lower doses of rFVIIa are also efficient. As well as that, the concomitant use of FFP and rFVIIa allows the reduction of rFVIIa dosage.

Abstract


Background: Severe perioperative bleedings related to major surgeries pose a serious medical problem due to surgical treatment. NovoSeven (recombinant activated factor VII - rFVIIa, Novo Nordisk, Denmark) accelerates local haemostasis by an exogenous coagulation system, directly stimulating factor X.
Material i methods: Three cases of the successful use of rFVIIa in the Department of General and Vascular Surgery of Poznan University of Medical Sciences have been described. The first case refers to the controlling of bleeding from a surgical wound in a female patient with idiopathic thrombocytopenia. The two others refer to the application of rFVIIa in female patients, who previously did not present any signs of haemostatic disorders.
Results: In all the cases presented, shortly after the drug’s administration, bleeding symptoms abated as confirmed by normalisation of laboratory results and haemodynamic parameters, which standard treatments had failed to produce before.
Conclusions: It is important to note that all the patients were administered a lower dose of rFVIIa than recommended by the manufacturer and described by other authors, which may indicate that lower doses of rFVIIa are also efficient. As well as that, the concomitant use of FFP and rFVIIa allows the reduction of rFVIIa dosage.
Get Citation

Keywords

haemorrhage; blood coagulation; haemostasis; recombinant activated factor VII; thrombocytopenia

About this article
Title

Clinical application of recombinant coagulation factor VIIa in the treatment of massive bleeding in surgical patients

Journal

Chirurgia Polska (Polish Surgery)

Issue

Vol 9, No 1 (2007)

Pages

34-42

Published online

2007-02-01

Bibliographic record

Chirurgia Polska 2007;9(1):34-42.

Keywords

haemorrhage
blood coagulation
haemostasis
recombinant activated factor VII
thrombocytopenia

Authors

Grzegorz Oszkinis
Magdalena Snoch
Fryderyk Pukacki
Marcin Gabriel
Maciej Zieliński
Marek Nowak
Katarzyna Motowidło
Paweł Sobczyński
Małgorzata Nowicka

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaBy "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl